Raymond James initiated coverage of Monopar Therapeutics (MNPR) with a Strong Buy rating and $80 price target Even with the stock’s 60% rally in 2025, the market continues to discount the upside potential from the newly acquired ALXN1840 for Wilson disease, the analyst tells investors in a research note. The firm sees additional upside in the shares and recommends buying at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR: